Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.50 |
| ▸ | GAA | P10253 | 6/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | GLA | P06280 | 4/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PTPRC | P08575 | 1/20 | 0.45 |
| ▸ | S100A4 | P26447 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10712504 | 0.93 | MAPT (0.55) | MAPTALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL617317 | 0.81 | KDM4E (0.58) | ALDH1A1NPC1RAB9AKDM4EHPGD | |
| SCHEMBL8138279 | 0.80 | KDM4E (0.47) | MAPTALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL6266913 | 0.80 | NPC1 (0.41) | MAPTALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL11103515 | 0.80 | KDM4E (0.63) | ALDH1A1NPC1RAB9AKDM4EGAA | |
| SCHEMBL8797468 | 0.80 | ALDH1A1 (0.42) | MAPTALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL8539954 | 0.80 | NPC1 (0.44) | MAPTALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL10637355 | 0.80 | AKR1B1 (0.48) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL8566926 | 0.79 | HDAC3 (0.53) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL13339672 | 0.78 | HDAC3 (0.53) | ALDH1A1NPC1RAB9AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994079-A | Method for synthesizing chromone, 1-thiochromone and gamma-pyrone compounds | 中国科学院上海药物研究所 | 2024-11-22 | — | — | CN | disclosed |
| EP-2714697-B1 | SPIRO-[1,3]-OXAZINES AND SPIRO-[1,4]-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2016-08-31 | — | — | EP | disclosed |
| US-9079919-B2 | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2015-07-14 | — | — | US | disclosed |
| WO-2012163790-A1 | SPIRO-[1,3]-OXAZINES AND SPIRO-[1,4]-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-06 | — | — | WO | disclosed |
| US-20120302549-A1 | SPIRO-[1,3]-OXAZINES AND SPIRO-[1,4]-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-11-29 | — | — | US | disclosed |
| EP-0230379-B1 | CHROMAN- AND THIOCHROMAN-4-ACETIC ACIDS USEFUL IN THE TREATMENT OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1991-04-03 | — | — | EP | disclosed |
| US-4853410-A | Hydroxyacetic acid derivatives for the treatment of diabetic complications | PFIZER INC. (US) | 1989-08-01 | — | — | US | disclosed |
| EP-0230379-A2 | Chroman- and thiochroman-4-acetic acids useful in the treatment of diabetic complications | PFIZER INC. (US) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302549-A1 | SPIRO-[1,3]-OXAZINES AND SPIRO-[1,4]-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE1, BACE2, PSEN1 | MAPT 123/4885ALDH1A1 126/4885NPC1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.